Xenon Pharmaceuticals Inc（XENE）の株式分析XENEXenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS), and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD), and bipolar depression (BPD). The Company is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Xenon Pharmaceuticals is not a good buy right now due to its current price of $33.49 and a very low RSI of 19.222, indicating oversold conditions. The stock has dropped 25% recently due to a pause in patient enrollment for clinical studies, which raises concerns about its near-term growth prospects. Although there are positive analyst ratings with targets as high as $73, the significant recent decline and ongoing financial losses, including a net loss of $110.7 million in Q2 2026, present considerable risks. The main risk is the company's ongoing financial struggles, as evidenced by a forward P/E ratio of 0 and a price-to-sales ratio of 0, indicating no current revenue generation. Therefore, it is advisable to sell or hold off on purchasing until the situation stabilizes.

3 analysts cover XENE: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 54.09.